2020
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Journal Of The American Academy Of Dermatology 2020, 82: e223-e226. PMID: 32278797, PMCID: PMC7144601, DOI: 10.1016/j.jaad.2020.03.099.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, RheumatoidAzetidinesBetacoronavirusColitis, UlcerativeCoronavirus InfectionsCOVID-19CytokinesDermatitis, AtopicHeterocyclic Compounds, 3-RingHumansImmunomodulationJanus KinasesNitrilesPandemicsPiperidinesPneumonia, ViralPrimary MyelofibrosisPurinesPyrazolesPyrimidinesPyrrolesRandomized Controlled Trials as TopicSARS-CoV-2STAT Transcription FactorsSulfonamidesTreatment of severe lichen planus with the JAK inhibitor tofacitinib
Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. Journal Of Allergy And Clinical Immunology 2020, 145: 1708-1710.e2. PMID: 32018031, DOI: 10.1016/j.jaci.2020.01.031.Peer-Reviewed Original ResearchJAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients
Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients. Journal Of Investigative Dermatology 2020, 140: 1446-1449.e4. PMID: 31954727, DOI: 10.1016/j.jid.2019.12.019.Peer-Reviewed Original Research
2019
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata
Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. Journal Of The American Academy Of Dermatology 2019, 85: 743-745. PMID: 31499158, DOI: 10.1016/j.jaad.2019.08.080.Peer-Reviewed Original ResearchJanus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients
2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesisResponse to tofacitinib therapy of eyebrows and eyelashes in alopecia areata
Liu LY, King BA. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 1778-1779. PMID: 30502414, DOI: 10.1016/j.jaad.2018.11.037.Peer-Reviewed Original ResearchRuxolitinib for the treatment of severe alopecia areata
Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 566-568. PMID: 30195572, DOI: 10.1016/j.jaad.2018.08.040.Peer-Reviewed Original ResearchTofacitinib for the treatment of alopecia areata in preadolescent children
Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. Journal Of The American Academy Of Dermatology 2018, 80: 568-570. PMID: 30195571, DOI: 10.1016/j.jaad.2018.08.041.Peer-Reviewed Original ResearchRapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy
Kim R, Heaton H, Liu LY, King BA. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. JAMA Dermatology 2018, 154: 370-371. PMID: 29387870, DOI: 10.1001/jamadermatol.2017.5778.Peer-Reviewed Original Research
2017
Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life
Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. Journal Of The American Academy Of Dermatology 2017, 78: 597-599.e2. PMID: 29128459, DOI: 10.1016/j.jaad.2017.10.046.Peer-Reviewed Original ResearchTofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. Journal Of The American Academy Of Dermatology 2017, 78: 403-404.e1. PMID: 29108908, DOI: 10.1016/j.jaad.2017.10.043.Peer-Reviewed Original ResearchRepigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal Of The American Academy Of Dermatology 2017, 77: 675-682.e1. PMID: 28823882, PMCID: PMC6233876, DOI: 10.1016/j.jaad.2017.05.043.Peer-Reviewed Original ResearchConceptsTreatment of vitiligoJAK inhibitorsConsecutive patientsInhibitor tofacitinibJanus kinase inhibitor tofacitinibJAK inhibitor monotherapyRetrospective case seriesUltraviolet B phototherapyT-cell mediatorsBody surface areaJanus kinase inhibitorSeverity of diseaseB phototherapyInhibitor monotherapyCase seriesAutoimmune responseCell mediatorsAutoimmune diseasesCutaneous depigmentationLight exposureRetrospective natureStudy populationExisting therapiesControl groupTofacitinibJAK inhibitors in dermatology: The promise of a new drug class
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataAnti-Inflammatory AgentsAzetidinesClinical Trials as TopicDermatitis, AtopicDermatologic AgentsHumansJanus KinasesMolecular Targeted TherapyNitrilesPiperidinesProtein Kinase InhibitorsPsoriasisPurinesPyrazolesPyrimidinesPyrrolesSignal TransductionSkin DiseasesSulfonamidesVitiligoConceptsJAK inhibitorsSoluble inflammatory mediatorsNew drug classesUseful therapeutic strategyDifferent proinflammatoryAtopic dermatitisInflammatory mediatorsInflammatory dermatosesAlopecia areataDrug classesJanus kinase-signal transducerTherapeutic strategiesJAK inhibitionDermatologic therapyKinase-signal transducerTargeted therapeuticsActivator of transcriptionDermatologyJAK-STATInhibitorsPromising new classEarlier reportsInhibition
2016
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal Of Investigative Dermatology 2016, 137: 951-954. PMID: 27887955, PMCID: PMC5387413, DOI: 10.1016/j.jid.2016.10.044.Peer-Reviewed Original ResearchTofacitinib for the treatment of alopecia areata and variants in adolescents
Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal Of The American Academy Of Dermatology 2016, 76: 29-32. PMID: 27816292, DOI: 10.1016/j.jaad.2016.09.006.Peer-Reviewed Original ResearchConceptsAlopecia areataAdverse eventsAdolescent patientsTreatment of AASignificant hair regrowthUse of tofacitinibMonths of treatmentProspective clinical trialsMedian percent changeJanus kinase inhibitorSeverity of diseaseReview of systemsSALT scoreAlopecia ToolLaboratory monitoringPhysical examinationHair regrowthClinical trialsEffective therapyPromising therapyRetrospective natureTofacitinibControl groupPatientsPercent changeTofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Journal Of The American Academy Of Dermatology 2016, 76: 22-28. PMID: 27816293, DOI: 10.1016/j.jaad.2016.09.007.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisPercent changeAlopecia Tool (SALT) scorePatients age 18Primary end pointSerious adverse eventsMonths of treatmentCommon autoimmune disorderSeries of patientsScalp hair lossAdverse eventsClinical responseHigher percent changeAutoimmune disordersRetrospective studyEffective therapyRetrospective natureInclusion criteriaHair lossPotential respondersPatientsTool scoreSafety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge M, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016, 1: e89776. PMID: 27699252, PMCID: PMC5033755, DOI: 10.1172/jci.insight.89776.Peer-Reviewed Original ResearchConceptsAlopecia areataAlopecia totalisAlopecia universalisHair lossDisease activity index scoreTreatment of AANational Alopecia Areata FoundationActivity index scoreCompletion of therapySevere alopecia areataSingle-arm trialNational Psoriasis FoundationScalp hair lossNational InstituteVeterans Affairs OfficePan-JAK inhibitorAdverse eventsDrug cessationDurable responsesAlopecia ToolDisease relapseTherapeutic optionsAutoimmune diseasesEffective therapyGrade ITofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Dhayalan A, King BA. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. JAMA Dermatology 2016, 152: 1-2. PMID: 26630079, DOI: 10.1001/jamadermatol.2015.3772.Peer-Reviewed Original Research
2015
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology 2015, 151: 1110-1112. PMID: 26107994, DOI: 10.1001/jamadermatol.2015.1520.Peer-Reviewed Original ResearchConceptsJanus kinase inhibitorTreatment of vitiligoKinase inhibitorsPathogenesis-directed therapyPathogenesis of vitiligoOral JanusSignificant repigmentationTherapeutic optionsCommon conditionEffective treatmentVitiligoAdditional studiesTofacitinib citrateTreatmentInhibitorsPatientsPathogenesisRepigmentationTherapy